Cantor Fitzgerald analyst Brandon Folkes started Insys Therapeutics with an Overweight rating and $9 price target. The analyst sees 2019 as a “pivotal and transformational year” for Insys with two potential filings with its spray platform along with two data readouts from its cannabinoids platform. 2019 could be the year in which investors are able to return to Insys and “appreciate the value which could be unlocked from within the company’s spray and cannabinoids pipeline,” Folkes tells investors in a research note.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.